TY - JOUR
T1 - Structural Basis of Interactions between Human Glutamate Carboxypeptidase II and Its Substrate Analogs
AU - Barinka, Cyril
AU - Hlouchova, Klara
AU - Rovenska, Miroslava
AU - Majer, Pavel
AU - Dauter, Miroslawa
AU - Hin, Niyada
AU - Ko, Yao Sen
AU - Tsukamoto, Takashi
AU - Slusher, Barbara S.
AU - Konvalinka, Jan
AU - Lubkowski, Jacek
N1 - Funding Information:
We thank Jana Starkova for the excellent technical assistance, Zbigniew Dauter for help with data collection, and Drs. James K. Coward and Nadya Valiaeva (University of Michigan) for their generous gift of MPE. Diffraction data were collected at the Southeast Regional Collaborative Access Team beamline 22-ID at the Advanced Photon Source, Argonne National Laboratory. Use of the Advanced Photon Source was supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract No. W-31-109-Eng38. This project was supported in part by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research (J.L. and C.B.). J.K., M.R., and K.H. were in part supported by the Ministry of Education of the Czech Republic (Research Centre for New Antivirals and Antineoplastics, 1M0508).
PY - 2008/3/7
Y1 - 2008/3/7
N2 - Human glutamate carboxypeptidase II (GCPII) is involved in neuronal signal transduction and intestinal folate absorption by means of the hydrolysis of its two natural substrates, N-acetyl-aspartyl-glutamate and folyl-poly-γ-glutamates, respectively. During the past years, tremendous efforts have been made toward the structural analysis of GCPII. Crystal structures of GCPII in complex with various ligands have provided insight into the binding of these ligands, particularly to the S1′ site of the enzyme. In this article, we have extended structural characterization of GCPII to its S1 site by using dipeptide-based inhibitors that interact with both S1 and S1′ sites of the enzyme. To this end, we have determined crystal structures of human GCPII in complex with phosphapeptide analogs of folyl-γ-glutamate, aspartyl-glutamate, and γ-glutamyl-glutamate, refined at 1.50, 1.60, and 1.67 Å resolution, respectively. The S1 pocket of GCPII could be accurately defined and analyzed for the first time, and the data indicate the importance of Asn519, Arg463, Arg534, and Arg536 for recognition of the penultimate (i.e., P1) substrate residues. Direct interactions between the positively charged guanidinium groups of Arg534 and Arg536 and a P1 moiety of a substrate/inhibitor provide mechanistic explanation of GCPII preference for acidic dipeptides. Additionally, observed conformational flexibility of the Arg463 and Arg536 side chains likely regulates GCPII affinity toward different inhibitors and modulates GCPII substrate specificity. The biochemical experiments assessing the hydrolysis of several GCPII substrate derivatives modified at the P1 position, also included in this report, further complement and extend conclusions derived from the structural analysis. The data described here form an a solid foundation for the structurally aided design of novel low-molecular-weight GCPII inhibitors and imaging agents.
AB - Human glutamate carboxypeptidase II (GCPII) is involved in neuronal signal transduction and intestinal folate absorption by means of the hydrolysis of its two natural substrates, N-acetyl-aspartyl-glutamate and folyl-poly-γ-glutamates, respectively. During the past years, tremendous efforts have been made toward the structural analysis of GCPII. Crystal structures of GCPII in complex with various ligands have provided insight into the binding of these ligands, particularly to the S1′ site of the enzyme. In this article, we have extended structural characterization of GCPII to its S1 site by using dipeptide-based inhibitors that interact with both S1 and S1′ sites of the enzyme. To this end, we have determined crystal structures of human GCPII in complex with phosphapeptide analogs of folyl-γ-glutamate, aspartyl-glutamate, and γ-glutamyl-glutamate, refined at 1.50, 1.60, and 1.67 Å resolution, respectively. The S1 pocket of GCPII could be accurately defined and analyzed for the first time, and the data indicate the importance of Asn519, Arg463, Arg534, and Arg536 for recognition of the penultimate (i.e., P1) substrate residues. Direct interactions between the positively charged guanidinium groups of Arg534 and Arg536 and a P1 moiety of a substrate/inhibitor provide mechanistic explanation of GCPII preference for acidic dipeptides. Additionally, observed conformational flexibility of the Arg463 and Arg536 side chains likely regulates GCPII affinity toward different inhibitors and modulates GCPII substrate specificity. The biochemical experiments assessing the hydrolysis of several GCPII substrate derivatives modified at the P1 position, also included in this report, further complement and extend conclusions derived from the structural analysis. The data described here form an a solid foundation for the structurally aided design of novel low-molecular-weight GCPII inhibitors and imaging agents.
KW - NAALADase
KW - folate hydrolase
KW - metallopeptidase
KW - phosphapeptide
KW - prostate-specific membrane antigen
UR - http://www.scopus.com/inward/record.url?scp=39149137206&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=39149137206&partnerID=8YFLogxK
U2 - 10.1016/j.jmb.2007.12.066
DO - 10.1016/j.jmb.2007.12.066
M3 - Article
C2 - 18234225
AN - SCOPUS:39149137206
SN - 0022-2836
VL - 376
SP - 1438
EP - 1450
JO - Journal of molecular biology
JF - Journal of molecular biology
IS - 5
ER -